CSIMarket Company Name, Ticker, Industry, else..


Elite Pharmaceuticals Inc   (ELTP)
Other Ticker:  
 

Elite Pharmaceuticals Inc

ELTP's Fundamental analysis



Looking into Elite Pharmaceuticals Inc growth rates, revenue grew by 127.93 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 111

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -0.28 %

Elite Pharmaceuticals Inc realized net income compared to net loss a year ago in IV. Quarter 2024

• More on ELTP's Growth


Elite Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Elite Pharmaceuticals Inc PEG ratio is at -0.01 Elite Pharmaceuticals Inc realized cash reduction of $ -0 per share in trailing twelve-month period.
Company
25.4
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 7.17.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.77.


• More on ELTP's Valuation
 
 Total Debt (Millions $) 3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 841,151
 Net Income/Employee (TTM) $ 300,129
 Receivable Turnover (TTM) 4.32
 Tangible Book Value (Per Share $) 0.05

Elite Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Elite Pharmaceuticals Inc PEG ratio is at -0.01 Elite Pharmaceuticals Inc realized cash outflow of $ -0per share in trailing twelve-month period.
Company
25.4
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 7.17.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.77.

Elite Pharmaceuticals Inc Price to Book Ratio is at 7.02 lower than Industry Avg. of 85.01. and higher than S&P 500 Avg. of 0

• More on ELTP's Valuation

•  Market Capitalization (Millions $) 404
•  Shares Outstanding (Millions) 1,005
•  Employees 67
•  Revenues (TTM) (Millions $) 56
•  Net Income (TTM) (Millions $) 20
•  Cash Flow (TTM) (Millions $) -1
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) 3
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 841,151
•  Net Income/Employee(TTM) $ 300,129
•  Receivable Turnover Ratio (TTM) 4.32
•  Tangible Book Value (Per Share $) 0.05

•  Market Capitalization (Millions $) 404
•  Shares Outstanding (Millions) 1,005
•  Employees 67
•  Revenues (TTM) (Millions $) 56
•  Net Income (TTM) (Millions $) 20
•  Cash Flow (TTM) (Millions $) -1
•  Capital Exp. (TTM) (Millions $) -1


    ELTP's Profitability Comparisons
Elite Pharmaceuticals Inc faced margin deterioration, primarily through cost control. Operating Margin fell in IV. Quarter 2024 to 19.5 % from 23.49 % in III. Quarter.

Elite Pharmaceuticals Inc net profit margin of 17.4 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 59 in Healthcare sector and number 717 in S&P 500.


Profitability by Segment
Total 4.7 %



  Ratio
•   Capital Ratio (MRQ) 3.07
•  Total Debt to Equity (MRQ) 0.04
•  Tangible Leverage Ratio (MRQ) 0.51
•  Asset Turnover Ratio (TTM) 0.81
•  Inventory Turnover Ratio (TTM) 2.24



Elite Pharmaceuticals Inc faced margin deterioration, primarily through cost control. Operating Margin fell in IV. Quarter 2024 to 19.5 % from 23.49 % in III. Quarter.

Elite Pharmaceuticals Inc net profit margin of 17.4 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 59 in Healthcare sector and number 717 in S&P 500.

• More on ELTP's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com